A carregar...
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
BACKGROUND: Women of childbearing potential are often treated with monoclonal antibodies to control chronic and debilitating inflammatory diseases. Remicade(®) (innovator infliximab [IFX]) may cross the placenta after the first trimester of pregnancy. Hence, evidence is needed to optimize treatment...
Na minha lista:
| Publicado no: | Drug Saf |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007430/ https://ncbi.nlm.nih.gov/pubmed/31677004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40264-019-00881-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|